June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
XEN Gel Implant in Refractory Glaucoma: A Retrospective Study
Author Affiliations & Notes
  • Alexander Crane
    Rutgers New Jersey Medical School, New Jersey, United States
  • Gaurav Srivastava
    Chesapeake Eye Care and Laser Center, Maryland, United States
  • Albert S Khouri
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, New Jersey, United States
  • Footnotes
    Commercial Relationships   Alexander Crane, None; Gaurav Srivastava, None; Albert Khouri, Aerie (C), Allergan (C), Allergan (F), Bausch and Lomb (C), NJ Health Foundation (F), Optovue (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3132. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexander Crane, Gaurav Srivastava, Albert S Khouri; XEN Gel Implant in Refractory Glaucoma: A Retrospective Study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3132.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the efficacy and safety of the XEN45 Gelstent implant in patients with refractory glaucoma.

Methods : This is a retrospective, single center chart review conducted on consecutive glaucoma patients undergoing XEN45 Gel stent implantation from 2017-2019. Primary outcome was meeting success criteria, with complete success defined as 20% reduction in intra-ocular pressure (IOP) with no IOP lowering medications, and qualified success defined as 20% reduction in IOP with IOP lowering medications. IOP, visual acuity (VA), and number of glaucoma medications (GMs) were recorded pre-operatively, in addition to 3 and 6 months post-operatively (POM3 and POM6, respectively). Refractory glaucoma defined as previously failed filtering/shunting surgery or cycloablativeprocedure and/or uncontrolled IOP on maximally tolerated medical therapy. Exclusion criteria included lack of follow-up at POM3 or POM6. Significance determined by t-test, with alpha=0.05. Data presented as (mean +/- standard deviation) unless otherwise specified.

Results : Twenty-one patients with refractory glaucoma were identified; baseline characteristics include a mean age of 69, 7 females (33%), pre-op IOP (20.8 +/- 6.7 mmHg), and pre-op GMs (3.1 +/- 1.2).

At POM3 (n=12) IOP and GMs were significantly lower than pre-op (p<0.05), but there was no significant difference in VA. Complete success was achieved in 3 patients (25%) and qualified success was achieved in 6 patients (50%). At POM6 (n=6), complete success was achieved in 1 patient (17%) and qualified success in 4 patients (67%).

Conclusions :
XEN Gel stent implantation was successful in the short term for reducing IOP and number of medications in patients with refractory open angle glaucoma; however, further investigation with a larger sample size is necessary to understand long-term outcomes.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.